A Belgian Multicenter Phase II Randomized Trial in her2 Negative Metastatic Breast Cancer Evaluating Consolidation Antiangiogenic Therapy With SU11248 After Response to Taxane Chemotherapy Induction.

Trial Profile

A Belgian Multicenter Phase II Randomized Trial in her2 Negative Metastatic Breast Cancer Evaluating Consolidation Antiangiogenic Therapy With SU11248 After Response to Taxane Chemotherapy Induction.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Dec 2014

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms SUCON
  • Most Recent Events

    • 10 Dec 2009 Primary endpoint 'Progression free survival rate' has not been met.
    • 10 Dec 2009 Results were presented at the 32nd Annual San Antonio Breast Cancer Symposium.
    • 17 Nov 2009 Actual patient number (55) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top